Clinical Research Directory
Browse clinical research sites, groups, and studies.
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
To evaluate the time of response, sustained remission rate, and relapse rate of CD38 monoclonal antibody (Daratumumab) combined with SCT800 (rFVIII) in the treatment of hemophilia A adolescents and adults with high titer inhibitors.
Official title: The Outcome Comparison of Immune Tolerance Induction Therapy Using SCT800 Combined With Daratumumab or SCT800 Alone in Hemophilia A Adolescents and Adults With High Titer Inhibitor: a Non-randomized Controlled Trial
Key Details
Gender
All
Age Range
14 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-11-22
Completion Date
2026-12-01
Last Updated
2025-02-24
Healthy Volunteers
No
Conditions
Interventions
SCT800 and Daratumumab
SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
SCT800
SCT800 50IU/kg TIW alone
Locations (1)
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tianjin, China